Hepatitis C virus (HCV) infects more than 185 million individuals worldwide. Twenty percent of patients chronically infected with HCV progress to cirrhosis. New, simpler therapeutics using direct-acting antivirals that target various stages of the HCV life cycle are in development to eradicate HCV without concomitant interferon.
Chandler, AZ, April 27, 2024 / Today, we remember and honor a truly remarkable individual and…
AZ Liver's own Vicki McIntyre, DNP, FNP was featured on the popular Tucson morning show…
As part of its mission to educate the community about liver health, AZ Liver Health…
This article provides expert guidance on the management of pruritus symptoms in patients receiving obeticholic…
In this review we critically assess the literature to evaluate the level of risk posed…
The interferon (IFN)–free regimen of sofosbuvir and ribavirin for 24 weeks was recently approved to…